% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{McManus:269039,
      author       = {McManus, Róisín M. and Latz, Eicke},
      title        = {{NLRP}3 inflammasome signalling in {A}lzheimer's disease},
      journal      = {Neuropharmacology},
      volume       = {252},
      issn         = {0028-3908},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DZNE-2024-00470},
      pages        = {109941},
      year         = {2024},
      abstract     = {Every year, 10 million people develop dementia, the most
                      common of which is Alzheimer's disease (AD). To date, there
                      is no way to prevent cognitive decline and therapies are
                      limited. This review provides a neuroimmunological
                      perspective on the progression of AD, and discusses the
                      immune-targeted therapies that are in preclinical and
                      clinical trials that may impact the development of this
                      disease. Specifically, we look to the role of the NLRP3
                      inflammasome, its triggers in the brain and how its
                      activation can contribute to the progression of dementia. We
                      summarise the range of inhibitors targeting the NLRP3
                      inflammasome and its downstream pathways that are under
                      investigation, and discuss future therapeutic perspectives
                      for this devastating condition.},
      subtyp        = {Review Article},
      keywords     = {Animals / Humans / Alzheimer Disease: metabolism /
                      Alzheimer Disease: immunology / Alzheimer Disease: drug
                      therapy / Brain: metabolism / Brain: immunology /
                      Inflammasomes: metabolism / NLR Family, Pyrin
                      Domain-Containing 3 Protein: metabolism / NLR Family, Pyrin
                      Domain-Containing 3 Protein: antagonists $\&$ inhibitors /
                      Signal Transduction: physiology / Signal Transduction: drug
                      effects / Alzheimer's disease (Other) / Immune-targeted
                      therapies (Other) / Microglia (Other) / NLRP3 inflammasome
                      (Other) / Neuroimmunology (Other) / Preclinical models
                      (Other) / Inflammasomes (NLM Chemicals) / NLR Family, Pyrin
                      Domain-Containing 3 Protein (NLM Chemicals) / NLRP3 protein,
                      human (NLM Chemicals)},
      cin          = {AG Latz ; AG Latz / AG McManus},
      ddc          = {610},
      cid          = {I:(DE-2719)1013024 / I:(DE-2719)1013042},
      pnm          = {351 - Brain Function (POF4-351) / 352 - Disease Mechanisms
                      (POF4-352)},
      pid          = {G:(DE-HGF)POF4-351 / G:(DE-HGF)POF4-352},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38565393},
      doi          = {10.1016/j.neuropharm.2024.109941},
      url          = {https://pub.dzne.de/record/269039},
}